TABLE 3:

Hazard ratios and confidence intervals by attribute

Attribute	Grade III Gliomas			Glioblastomas
Attribute	HR	95% CI	P Value	HR	95% CI	P Value
Clinical
Age	3.74	1.09–12.9	.036	2.29	1.35–3.86	.002
KPS	0.96	0.93–0.99	.006	0.98	0.96–0.99	.005
Oligodendroglioma component	1.06	0.55–2.07	.854	0.58	0.34–0.99	.047
Resection	1.22	0.67–2.23	.517	1.08	0.85–1.37	.530
Imaging
Enhancing rim	1.68	0.34–8.37	.519	1.16	0.73–1.84	.522
SE	0.79	0.38–1.61	.508	1.04	0.66–1.63	.863
CE	3.30	0.71–15.3	.127	1.53	0.21–11.1	0.68
ECM	2.45	0.76–7.87	.134	1.33	0.81–2.21	.264
TCM	2.45	0.76–7.87	.134	1.31	0.72–2.36	.374
Location	0.97	0.63–1.52	.914	1.04	0.88–1.23	.639
Multifocal	18.7	3.06–115	.002	4.34	2.11–8.92	.001
Necrosis	4.43	1.35–14.6	.014	1.24	0.30–5.09	.764
nCET	0.05	0.01–0.55	.014	0.55	0.33–0.92	.023
EM	0.32	0.07–1.35	.121	0.64	0.37–1.12	.120
NEM	2.95	0.85–10.3	.089
Satellites	5.18	1.11–24.1	.036	1.74	1.03–2.93	.038
Side	0.80	0.17–3.79	.782	1.29	0.79–2.07	.300
Size	1.16	0.90–1.50	.235	1.05	0.94–1.17	.393
Cyst	0.03	0.00–20.8	.302	0.92	0.46–1.80	.799
Edema	1.99	0.79–3.99	.158	1.62	1.18–2.22	.003

Note.—HR indicates hazard ratio (of dying); KPS, Karnofsky performance status; SE, solid enhancement; CE, contrast enhancement; ECM, edema crosses midline; TCM, tumor crosses midline; nCET, noncontrast-enhancing tumor; EM, enhancing margin; NEM, nonenhancing margin.